Joan A.
- Country
- Spain
- Department
- Oncología Médica
Research Overview
- A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
- Phase I Study of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Advanced HER2-Positive Solid Tumors
- A Phase II Randomized, Double-Blind Study Comparing Fulvestrant and Palbociclib Versus Fulvestrant and Placebo in HR-Positive Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 41 of 177 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in the treatment of HER2-positive breast cancer, with particular emphasis on early-stage disease management and innovative therapeutic approaches.
- Early-stage breast cancer treatment
- HER2-targeted therapies
- Adjuvant treatment strategies
The investigator focuses on developing treatment pathways for patients with high recurrence risk following preoperative therapy.
Immunotherapy Applications
The investigator explores targeted immunotherapy approaches in breast cancer treatment, specifically investigating immune checkpoint inhibitor applications in combination with established therapies.
- Combination immunotherapy
- Novel treatment combinations
- Immune response in breast cancer
Their work centers on integrating immunotherapeutic agents into established treatment protocols for breast cancer.
Therapeutic Innovation
The investigator studies antibody-drug conjugates and their role in treating aggressive forms of breast cancer, with particular attention to reducing recurrence risks.
- Targeted antibody therapies
- Risk reduction strategies
- Treatment optimization
Their research emphasizes developing more effective therapeutic approaches for high-risk breast cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.